NewsBenzinga젠맙, 3상 RAINFOL-02 임상시험에서 진행성 난소암 치료제 ‘리나-S’의 무진행 생존기간(PFS) 및 주요 2차 전체 생존기간(OS) 지표 충족···통계적으로 유의미하고 임상적으로 의미 있는 개선 효과 입증 젠맙, 3상 RAINFOL-02 임상시험에서 진행성 난소암 치료제 ‘리나-S’의 무진행 생존기간(PFS) 및 주요 2차 전체 생존기간(OS) 지표 충족···통계적으로 유의미하고 임상적으로 의미 있는 개선 효과 입증 Benzinga 2026.10.23 15:57 (GMT+0) Open on Benzinga Other news Nvidia Forms Board Panel for Export-Control Oversight Musk Responds to Jensen Huang's X Account Losing Blue Checkmark and Nvidia Affiliate Badge: Will Restore Blue Check for Free NVIDIA Board Establishes National Security and Export Control Oversight Committee Is Wall Street Bullish or Bearish on Ferguson Enterprises Stock? Nvidia Board Not Considering Jensen Huang's Return: Report Lighter Releases Security Incident Statement: API Key Leak Led to User Fund Theft, About $5 Million in USDC Recovered
Musk Responds to Jensen Huang's X Account Losing Blue Checkmark and Nvidia Affiliate Badge: Will Restore Blue Check for Free
Lighter Releases Security Incident Statement: API Key Leak Led to User Fund Theft, About $5 Million in USDC Recovered